Defining molecular glues with a dual-nanobody cannabidiol sensor
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index; 15 of the 40 sources its claims cite were checked for support.
Abstract
“Molecular glue” (MG) is a term coined to describe the mechanism of action of the plant hormone auxin and subsequently used to characterize synthetic small molecule protein degraders exemplified by immune-modulatory imide drugs (IMiDs). Prospective development of MGs, however, has been hampered by its elusive definition and thermodynamic characteristics. Here, we report the crystal structure of a dual-nanobody cannabidiol-sensing system, in which the ligand promotes protein-protein interaction in a manner analogous to auxin. Through quantitative analyses, we draw close parallels among the dual-nanobody cannabidiol sensor, the auxin perception complex, and the IMiDs-bound CRL4 CRBN E3, which can bind and ubiquitinate “neo-substrates”. All three systems, including the recruitment of IKZF1 and CK1α to CRBN, are characterized by the lack of ligand binding activity in at least one protein partner and an under-appreciated preexisting low micromolar affinity between the two proteinaceous subunits that is enhanced by the ligand to reach the nanomolar range. These two unifying features define MGs as a special class of proximity inducers distinct from bifunctional compounds and can be used as criteria to guide target selection for future rational discovery of MGs.
Overview
CoChat Summary
TL;DR
The paper reports the 2.0 Å crystal structure of a dual-nanobody cannabidiol sensor and uses quantitative biophysics to compare it with auxin and IMiD systems. It proposes that molecular glues are defined by no detectable ligand affinity to at least one protein partner plus a preexisting low-micromolar affinity between the two protein partners that the ligand enhances to the nanomolar range.
Key findings
- The CA14-CBD-DB21 ternary complex was determined at 2.0 Å; CBD is buried at the nanobody interface, the complex buries ~1400 Ų with about two-thirds contributed by protein–protein interactions, and the channel is too narrow for CBD to enter or escape without nanobody dissociation.
- In the CBD sensor, CA14 binds CBD with 2.2 μM affinity, DB21 shows no detectable CBD affinity, DB21 binds CBD-bound CA14 with Kd 43 nM, and ligand-free CA14-DB21 has ~20 μM affinity; CBD enhances the interaction ~450-fold. D34A in CA14 disables the response, while DB21 F48A/H101A mutations reduce enhancement to ~10-fold.
- In the auxin system, TIR1 binds auxin with 13.4 μM affinity, Aux/IAA7 shows no detectable auxin affinity, TIR1-IAA7 affinity is 30.5 nM with auxin versus ~18–20 μM without auxin, giving ~600-fold enhancement.
- For IMiDs, DDB1–CRBN has intrinsic affinity for IKZF1 at 200–300 nM, increased by pomalidomide to 50–70 nM, and for CK1α at 2.3 μM, increased by lenalidomide to 75 nM. The paper defines MGs by lack of detectable affinity to at least one partner plus quantifiable intrinsic protein–protein affinity, with positive cooperativity and a sigmoid dose-response lacking a hook effect.
Methods
- Crystallized the CA14-CBD-DB21 ternary complex, collected X-ray data at 2.0 Å, and solved the structure by molecular replacement; nanobodies were expressed in E. coli periplasm, purified, and assembled with CBD.
- Measured ligand binding by ITC and protein–protein affinities by BLI and AlphaScreen competition assays in the absence or presence of saturating MG; performed structure-guided mutagenesis of CA14 D34 and DB21 F48/H101.
- Built a three-body equilibrium model for topologically trapped MGs, simulated dose-response curves using Kd1, Kd2, and protein concentrations, and validated predictions with AlphaScreen CBD and auxin dose-response experiments.
Limitations
- Stated: CA14 remained refractory to crystallization, so the contribution of the CBD-DB21 interface was assessed by mutagenesis rather than direct apo/binary CA14 structures; the paper also notes the open question of what affinity range is amenable to diffusible MG compounds.
- Evident: The proposed MG definition is derived from a small set of systems—an engineered CBD sensor, auxin, and IMiDs—and from in vitro binding assays; generalizability to all molecular glues and cellular contexts is not established by this study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






![Fig. 7 Mathematical simulation of MG system. a, b Topology and equilibria of a general and topologically trapped MG system. For the topologically trapped MG system, MG (orange) is buried at the protein interface and cannot enter its binding site if the binary protein complex between the Receptor (green) and the dimerization partner (blue) is formed first. R receptor, D dimerization partner, R•MG the receptor-MG binary complex, R•D the binary complex of receptor-dimerization partner, and R•MG•D the ternary complex of receptor-MG-dimerization partner. Four equilibrium dissociation constants, Kd1 (R,MG), Kd2 (R•MG,D), Kd3 (R,D), and Kd4 (R•D,MG), represent the affinity between R and MG, R•MG and D, R and D, and R•D and MG, respectively. c MG dose-response curve calculated by a mathematical model. d, e Experimentally detected MG dose-response curve for CBD and auxin, respectively. Data were presented as mean ± s.d. of n = 3 biologically independent samples. EC50, half-maximum response concentration. Source data are provided as a Source Data file. f Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd1 and variable Kd2. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd2 value. g Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd2 and variable Kd1. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd1 value. h, i Simulation of CBD dose-response curve with variable total protein concentrations [CA14] and [DB21]. Ternary complex (%) represents [CA14•CBD•DB21]/[CA14•CBD•DB21]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing identical [CA14] and [DB21] value. j, k Simulation of auxin dose-response curve with fixed total [TIR1] and variable [IAA7]. Ternary complex (%) represents [TIR1•auxin•IAA7]/[TIR1•auxin•IAA7]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing [IAA7] value.](https://figures.cochat.ai/paper-figures/bc41c59206954ae2be54e0e997fcfd79/defining-molecular-glues-with-a-dual-nanobody-cannabidiol-sensor-figure-7.jpg)
Verification
Claims the paper makes
6 Valid · 1 Not valid · 8 Not checked · 74 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Even higher cooperativity is achieved by the rationally developed NRX-252114 compound, which is capable of enhancing the binding between β-TrCP and a hypophosphorylated β-catenin degron (pSer33/Ala37) peptide by 680-folds38.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Results > Cooperativity of MGs
What the sources say
- Disputedcites [38] Simonetta, K. R. et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat. Commun. 10, 1402 (2019). sourceExperimental — accuracy not yet measured
For the exact peptide named in the claim (monophosphorylated pSer33/S37A, i.e. 'hypophosphorylated β-catenin degron pSer33/Ala37'), the Results section 'Optimized enhancers have improved potency and cooperativity' states NRX-252114 enhances β-TrCP binding with >1500-fold cooperativity, explicitly a lower limit because the assay bottoms out (Fig. 3 legend, same section). The only ~500–700-scale figure in our copy is for a different peptide — the fully unphosphorylated Ser33/Ser37 degron, enhanced from >100 µM to 180 nM (>500-fold) in 'Enhancers potentiate unphosphorylated β-catenin ubiquitylation'. No 680-fold value appears anywhere in our copy (searched: '680-fold cooperativity NRX-252114', 'NRX-252114 cooperativity fold enhancement pSer33/S37A'), so the magnitude attributed here conflicts with the paper's reported value. (LLM, conf=0.70)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a panel of CDK12 inhibitors have been shown to act as MGs to enable a neo-morphic interaction between CDK12 and DDB1, inducing CRL4-catalyzed Cyclin K ubiquitination and degradation27–29.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Introduction
What the sources say
- Supportedcites [27] Lv, L. et al. Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. Elife https://doi.org/10.7554/eLife.59994 (2020). source
The Introduction states that HQ461 recruits DDB1 to CDK12, enabling the DDB1-CUL4-RBX1 ligase to polyubiquitinate and degrade Cyclin K. The Discussion reports that two other studies found CDK12 inhibitors with the same mechanism, supporting the claim about multiple compounds. The paper does not suggest that all CDK12 inhibitors act this way. (LLM, conf=0.91)
- Supportedcites [28] Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199–1207 (2020). source
The Results section, “Identification of structurally distinct cyclin K degraders,” reports that dCeMM2/3/4 inhibit CDK12/13 activity. The Discussion states that these compounds promote CDK12:cyclin K binding to a DDB1:CUL4B complex, leading to cyclin K ubiquitination and degradation. The paper specifies CRL4B, a more precise designation than the claim’s CRL4. (LLM, conf=0.91)
- Partly supportedcites [29] Słabicki, M. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293–297 (2020). sourceExperimental — accuracy not yet measured
The “CR8 directs CDK12 to CRL4 core component” section shows that CR8 promotes CDK12–DDB1 binding, CUL4A–RBX1–DDB1-mediated cyclin K ubiquitination, and cyclin K degradation. The “CR8 phenylpyridine confers glue activity” section reports that other tested inhibitors also promoted binding and some ubiquitination, but DRF053, roscovitine, and flavopiridol did not induce cyclin K degradation in cells. Thus, this paper does not support degradation by the panel as a whole. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Without a ligand-binding pocket, classic neo-substrates of IMiDs-bound CRBN, such as IKZF1 and CK1α, are not expected to have an affinity towards the compounds12,15.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Results > Intrinsic affinity between CRBN and neo-substrates
What the sources say
- Partly supportedcites [12] Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science https://doi.org/10.1126/science.aat0572 (2018). sourceExperimental — accuracy not yet measured
Our copy supplies the framing but not the attributed conclusion. The Introduction states that thalidomide analogs bind CRBN and 'alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1', and that 'Transcription factors have remained challenging drug targets due to the absence of druggable active sites (14)' — the latter a general point about TFs credited to another reference, and the Discussion speaks of targeting 'undruggable' transcription factors. What the paper never says is that IKZF1 or CK1α lack a ligand-binding pocket and therefore have no affinity for the compounds themselves; no binary drug–substrate binding is measured or asserted, and CK1α appears only as a comparison for β-hairpin packing against pomalidomide (Structures section, citing ref. 6). Indeed the Structures and Discussion sections report direct side-chain contacts between the compound and the substrate ('IKZF1 Q146 forms the only side chain interaction with the compound'; 'direct contacts between thalidomide analogs and the ZF provide additional layers of specificity'), so the pocket-absence/no-affinity claim as applied to CK1α and as an explicit inference is not supported by this source. (LLM, conf=0.70)
- Not checked yetcites [15] Petzold, G., Fischer, E. S. & Thomä, N. H. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127–130 (2016). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, their weak interactions are echoed by the low μM affinities recently reported for the DCAF15-RBM39 and DDB1-CDK12-Cyclin K interacting partners22,29 as well as the bipartite degron of JAZ1 that docks to the F-box protein COI1 via an α-helix next to the binding pocket of jasmonate-isoleucine, another MG plant hormone45.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Discussion
What the sources say
- Not checked yetcites [22] Du, X. et al. Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820. Structure 27, 1625–1633.e1623 (2019). source
- Partly supportedcites [29] Słabicki, M. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293–297 (2020). sourceExperimental — accuracy not yet measured
In 'CR8 directs CDK12 to CRL4 core component' our copy does describe the DDB1–CDK12–cyclin K partnership as a weak interaction ('weak CDK12-cycK-DDB1 interaction was still detectable in the absence of the compound in vitro'), which supports the citing sentence's framing of weak MG protein-partner contacts. However, the affinity it quantifies for this complex is sub-micromolar, not low micromolar: 'CR8 stimulated binding between CDK12-cycK and DDB1 in the range of 100–500 nM depending on the experimental setup (Fig. 2c, Extended Data Fig. 4)', tightened 500- to 1000-fold by the compound per ITC. The related values in 'CR8 phenylpyridine confers glue activity' and 'CDK12-DDB1 interface imparts selectivity' are only expressed as relative decreases (two-fold for DRF053, three-fold for roscovitine, lower affinity for CDK13), and no low-μM Kd/Ki for DDB1–CDK12–cycK is stated anywhere in our copy, so the specific magnitude attributed here is not supported by this source. (LLM, conf=0.72)
- Partly supportedcites [45] Sheard, L. B. et al. Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature 468, 400–405 (2010). sourceExperimental — accuracy not yet measured
The structural part of the attribution is in our copy: 'Structural roles of the bipartite JAZ degron' describes the JAZ1 degron as bipartite (loop plus α-helix) with the conserved C-terminal α-helix binding the top surface of the COI1 LRR domain adjacent to the ligand-binding site, and suggests it 'may provide a low affinity anchor for docking the JAZ protein on COI1'. However, no low-micromolar Kd for the JAZ1–COI1 interaction is reported anywhere in our copy: the quantitative affinities given are nM Kd values for 3H-coronatine binding to the COI1–JAZ6/COI1–JAZ1 co-receptor (68 nM and 48 nM, 'COI1-JAZ complex as a JA co-receptor') and µM Ki values for the JA-Ile isomers competing at that site (1.8 µM and 18 µM), i.e. ligand affinities, not a measured protein–protein affinity. So the 'low µM affinity reported for JAZ1-COI1' element attributed to this source is unsupported, and the paper's own language for the helix is a hedged qualitative 'low affinity anchor' rather than a reported micromolar value. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“the thermodynamic cycle for ternary complex formation mediated by such compounds is distinct from that of bifunctional proximity inducers, which has been previously described36.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Results > A mathematical model for the auxin-like MG system
What the sources say
- Supportedcites [36] Douglass, E. F., Miller, C. J., Sparer, G., Shapiro, H. & Spiegel, D. A. A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092–6099 (2013). source
The citation is attached to the statement that the bifunctional proximity-inducer equilibrium has been described previously, not to the citing authors’ comparison with MGs. The source’s References note 7 defines its model as a linear A–B–C complex formed through a bridging species B, and Results and Discussion (Non-cooperative Equilibria) describes the A–B and B–C binding interactions. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
49 more claims
Create a free account to see all 89 claims and to verify the 25 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the large interface area involves extensive interactions between CRBN-MG and KAT2A, providing measurable affinity of KAT2A-CRBN in the absence of MG (54) and resembling the molecular recognition seen in immunoglobulin (Ig) binding to antigens.”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that baseline compatibility between the POI and the E3 is a necessary requirement for the formation of a ternary complex.61,239”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, recent evidence suggests that MGDs depend on a certain baseline affinity between E3 and POI in the absence of the respective small molecule.61”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, the Zheng lab postulated that most, if not all, MGs act on proteins that already have a basal propensity to interact with each other, thus also differentiating this pharmacology from bifunctional molecules like PROTACs.77”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [77]
In the citing paper
“However, recent studies have scaled-down these numbers to more realistic prospects: exhaustive thermodynamic characterization of prototypical MGs outlined that a minimum level of intrinsic affinity between E3 and target may be required.77”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Abstract
“All three systems, including the recruitment of IKZF1 and CK1α to CRBN, are characterized by the lack of ligand binding activity in at least one protein partner and an under-appreciated preexisting low micromolar affinity between the two proteinaceous subunits that is enhanced by the ligand to reach the nanomolar range.”
§ Defining molecular glues with a dual-nanobody cannabidiol sensor > Results > Intrinsic affinity between CRBN and neo-substrates
“IKZF1 displayed a robust affinity at 200–300 nM toward CRBN in complex with full-length DDB1, as measured in both BLI and AlphaScreen competition assays (Fig. 6a, b).”
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
The Phyre2 web portal for protein modeling, prediction and analysis
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015) · Nature Protocols · doi:10.1038/nprot.2015.053 · Cited by 9,652
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
Laskowski, R. A., & Swindells, M. B. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200227u · Cited by 6,471
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
The F-box protein TIR1 is an auxin receptor
Dharmasiri, N., Dharmasiri, S., & Estelle, M. (2005) · Nature · doi:10.1038/nature03543 · Cited by 2,083
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Cited by
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 210
“60,61,95).”
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Sasso, J. M., Tenchov, R., Wang, D., Johnson, L. S., Wang, X., & Zhou, Q. A. (2023) · Biochemistry · doi:10.1021/acs.biochem.2c00245 · Cited by 246
Targeted protein degradation via intramolecular bivalent glues
Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222
“This reinforces the emerging concept that molecular glue degraders often stabilize pre-existing, albeit functionally inconsequential E3–target interactions 41,45,46 and suggests that these affinities may be essential for (intra)-molecular glue degraders.”
BackgroundProximity-Based Modalities for Biology and Medicine
Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 196
Molecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 187
Metadata
- Authors
- Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Zheng, Ning
- Venue
- Nature Communications
- Published
- 2022-02-10
- Volume
- 13
- Issue
- 1
- Pages
- 815-815
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8831599
- OpenAlex
- W4211187930
- Cited by
- 125
- References
- 59
- Citations by year
- 2026: 25 · 2025: 40 · 2024: 28 · 2023: 21 · 2022: 11
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Health & Human Services | National Institutes of Health (1R35GM128918, R21DA051555, R21DA051194)
- University of Washington Innovation Award
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Keywords
- molecular glues, cannabidiol, auxin perception, protein-protein interaction, cereblon, CRL4 E3 ubiquitin ligase, IKZF1, CK1α, protein degraders, crystal structure
- MeSH terms
- Lenalidomide, Adhesives, Cannabidiol, Indoleacetic Acids, Models, Molecular, Protein Binding, Substrate Specificity, Casein Kinase Ialpha, Nanostructures, Ikaros Transcription Factor, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining molecular glues with a dual-nanobody cannabidiol sensor. https://app.cochat.ai/papers/10.1038/s41467-022-28507-1
- The paper
- Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022). Defining molecular glues with a dual-nanobody cannabidiol sensor. Nature Communications. https://doi.org/10.1038/s41467-022-28507-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.